TARSTarsus Pharmaceuticals, Inc.

1. Sep 10, 2026On September 4, 2026 (the “Closing Date”), Tarsus Pharmaceuticals, Inc. (the “Company”) completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a Delaware corporation (“Alkeus”), pursuant to that certain Agreement and Plan of Merger, dated as of July 31, 2026 (the “Merger Agreement”), by and …Acquisition or disposition completed · Form 8-K
2. Aug 6, 2026Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth.Earnings release · press release
3. Aug 6, 2026On August 5, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a syndicate of existing and new healthcare investors (the “Investors”) for a private placement of: (i) 2,098,519 shares (the “Initial Shares”) of common stock, par …Material agreement entered · Form 8-K
4. Aug 6, 2026Merger Agreement On July 31, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alkeus Pharmaceuticals, Inc., a Delaware corporation (“Alkeus”), Apex 2026 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company …Material agreement entered · Form 8-K
5. Jul 13, 2026On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.Director or officer change · Form 8-K
6. Jul 8, 2026On July 6, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with iRenix Medical, Inc., a Delaware corporation (“iRenix”), Dolores Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) and Fortis …Material agreement entered · Form 8-K
7. May 6, 2026Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements.Earnings release · press release
8. Feb 23, 2026Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements.Earnings release · press release
9. Feb 18, 2026On February 18, 2026, the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), expanded the size of the Board from seven to eight directors and appointed David E.I. Pyott to the …Director or officer change · Form 8-K
10. Nov 4, 2025Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.